Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Infectious Disease Reports
Erschienen in: Current Infectious Disease Reports 1/2013

01.02.2013 | HIV/AIDS (R MacArthur, Section Editor)

The Immune Reconstitution Inflammatory Syndrome: A Clinical Update

verfasst von: Wendy S. Armstrong

Erschienen in: Current Infectious Disease Reports | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

The immune reconstitution inflammatory syndrome (IRIS) is a well-described phenomenon in HIV-infected patients following initiation of antiretroviral therapy and can lead to significant morbidity and mortality in some patients. Risk for IRIS is enhanced in those with low CD4 counts and preexisting opportunistic infections. The development of pathogen-specific definitions of IRIS has aided classification of patients and has facilitated research. Newer data on optimal timing of ART initiation, with additional data in the setting of tuberculosis and cryptococcal meningitis, will help guide strategies to decrease the risk of IRIS but must balance the risks of HIV disease progression. Managing patients with IRIS can be challenging. Treatment options include pathogen-specific therapy, antiinflammatory therapies, and other novel approaches.
Literatur
1.
• Lawn SD, Meintjes G. Pathogenesis and prevention of immune reconstitution disease during antiretroviral therapy. Expert Rev Anti Infect Ther. 2011;9:415–30. Excellent recent review highlighting current understanding of pathogenesis and risk factors for disease.PubMedCrossRef
2.
Sun H-Y, Singh N. Opportunistic infection-associated immune reconstitution syndrome in transplant recipients. Clin Infect Dis. 2011;53:168–76.PubMedCrossRef
3.
Shelburne SA, Montes M, Hamill RJ. Immune reconstitution inflammatory syndrome: more answers, more questions. J Antimicrob Chemother. 2006;57:167–70.PubMedCrossRef
4.
•• Meintjes G, Scriven J, Marais S. Management of the immune reconstitution inflammatory syndrome. Curr HIV/AIDS Rep. 2012;9:238–50. Thorough review of management recommendations, many based on authors opinions who are leaders in this field.PubMedCrossRef
5.
Kelley CF, Armstrong WS. Update on immune reconstitution inflammatory syndrome: progress and unanswered questions. Curr Infect Dis Rep. 2009;11:486–93.PubMedCrossRef
6.
French MAH, Mallal SA, Dawkins RL. Zidovudine induced restoration of cell-mediated immunity to mycobacteria in immunodeficient HIV-infected patients. AIDS. 1992;6:1293–7.PubMedCrossRef
7.
Shelburne III SA, Hamill RJ, Rodriguez-Barradas MC, et al. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore). 2002;81:213–27.CrossRef
8.
French MA, Price P, Stone SF. Immune restoration disease after antiretroviral therapy. AIDS. 2004;18:1615–27.PubMedCrossRef
9.
Robertson J, Meier M, Wall J, et al. Immune reconstitution syndrome in HIV: validation of a case definition and identifying clinical predictors in persons initiation antiretroviral therapy. Clin Infect Dis. 2006;42:1639–46.PubMedCrossRef
10.
Meintjes G, Lawn SD, Scano F, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis. 2008;8:516–23.PubMedCrossRef
11.
Haddow LJ, Colebunders R, Meintjes G, et al. Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitions. Lancet Infect Dis. 2010;10:791–802.PubMedCrossRef
12.
Manabe YC, Campbell JD, Sydnor E, et al. Immune reconstitution inflammatory syndrome: risk factors and treatment implications. J Acquir Immune Defic Syndr. 2007;46:456–62.PubMedCrossRef
13.
• Muller M, Wandel S, Colebunders R, et al. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10:251–61. Meta-analysis of 54 studies to assess rates of disease and mortality by pathogen and overall.PubMedCrossRef
14.
• Martin-Blondel G, Mars LT, Liblau RS. Pathogenesis of the immune reconstitution inflammatory syndrome in HIV-infected patients. Curr Opin Infect Dis. 2012;25:312–20. Detailed well written review of current data regarding disease pathogenesis.PubMedCrossRef
15.
Price P, Morahan G, Huang D, et al. Polymorphisms in cytokine genes define subpopulations of HIV-1 patients who experienced immune restoration diseases. AIDS. 2002;16:2043–7.PubMedCrossRef
16.
•• Weisner DL, Boulware DR. Cryptococcus-related immune reconstitution inflammatory syndrome (IRIS): pathogenesis and its clinical implications. Curr Fungal Infect Rep. 2011;5:252–61. Superb discussion of cryptococcal IRIS and pathogenesis of this disease by leading researcher in this area.CrossRef
17.
Zolopa AR, Andersen J, Komarow L, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: A multicenter randomized strategy trial. PLoS One. 2009;4:e5575.PubMedCrossRef
18.
Blanc F-X, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med. 2011;365:1471–81.PubMedCrossRef
19.
Abdool-Karim SS, Naidoo K, Grobler A, et al. Integration of antiretroviral therapy with tuberculosis treatment. New Engl J Med. 2011;365:1492–501.PubMedCrossRef
20.
Havlir DV, Kendall MA, Ive P, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. New Engl J Med. 2011;365:1482–91.PubMedCrossRef
21.
•• Naldoo K, Yende-Zuma N, Padayatchi N, et al. The immune reconstitution inflammatory syndrome after antiretroviral therapy initiation in patients with tuberculosis: findings from the SAPiT trial. Ann Int Med. 2012;157:313–24. Subanalysis from SAPiT specifically focused on IRIS cases in this landmark study of ART initiation in TB.
22.
Makadzange AT, Ndhlovu CE, Takarinda K, et al. Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-saharan Africa. Clin Infect Dis. 2010;50:1532–8.PubMedCrossRef
23.
Grant PM, Aberg JA, Zolopa AR. Concerns regarding a randomized study of the timing of antiretroviral therapy in Zimbabweans with AIDS and acute cryptococcal meningitis (letter). Clin Infect Dis. 2010;51:984–5.PubMedCrossRef
24.
25.
Meintjes G, Wilkinson RJ, Morroni C, et al. Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS. 2010;24:2381–90.PubMed
26.
Tan K, Roda R, Ostrow L, et al. PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids. Neurology. 2009;72:1458–64.PubMedCrossRef
27.
Pires A, Nelson M, Pozniak AL, et al. Mycobacterial immune reconstitution inflammatory syndrome in HIV-1 infection after antiretroviral therapy is associated with deregulated specific T-cell responses: beneficial effect of IL-2 and GM-CSF immunotherapy. J Immune Based Ther Vaccines. 2005;3:7.PubMedCrossRef
28.
Riddell 4th J, Kaul DR, Karakousis PC, et al. Mycobacterium avium complex immune reconstitution inflammatory syndrome: long term outcomes. J Transl Med. 2007;5:50.PubMedCrossRef
29.
Desimone Jr JA, Babinchak TJ, Kaulback KR, et al. Treatment of Mycobacterium avium complex immune reconstitution disease in HIV-1 infected individuals. AIDS Pt Care STDs. 2003;17:619–22.
30.
Cinti SK, Kaul DR, Sax PE, et al. Recurrence of Mycobacterium avium infection in patients receiving highly active antiretroviral therapy and antimycobacterial agents. Clin Infect Dis. 2000;30:511–4.PubMedCrossRef
31.
Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009;360:1815–26.PubMedCrossRef
32.
Dhasmana DJ, Dheda K, Ravn P, et al. Immune reconstitution inflammatory syndrome in HIV-infected patients receiving antiretroviral therapy: pathogenesis, clinical manifestations and management. Drugs. 2008;68:191–208.PubMedCrossRef
33.
Lehloenya R, Meintjes G. Dermatologic manifestations of the immune reconstitution inflammatory syndrome. Dermatol Clin. 2006;24:549–70.PubMedCrossRef
Metadaten
Titel
The Immune Reconstitution Inflammatory Syndrome: A Clinical Update
verfasst von
Wendy S. Armstrong
Publikationsdatum
01.02.2013
Verlag
Current Science Inc.
Erschienen in
Current Infectious Disease Reports / Ausgabe 1/2013
Print ISSN: 1523-3847
Elektronische ISSN: 1534-3146
DOI
https://doi.org/10.1007/s11908-012-0308-y

Weitere Artikel der Ausgabe 1/2013

Current Infectious Disease Reports 1/2013 Zur Ausgabe

HIV/AIDS (R MacArthur, Section Editor)

Organ Transplantation and HIV Progress or Success? A Review of Current Status

Intra-abdominal Infections, Hepatitis, and Gastroenteritis (D Bobak, Section Editor)

Treatment Options for Hepatitis Delta Virus Infection

HIV/AIDS (R MacArthur, Section Editor)

The Hispanic HIV Epidemic

HIV/AIDS (R MacArthur, Section Editor)

Neurologic Complications and Considerations in HIV-Infected Persons

HIV/AIDS (R MacArthur, Section Editor)

HCV Enters the Twenty-First Century

Intra-abominal Infections, Hepatitis, and Gastroenteritis (D Bobak, Section Editor)

Lessons Learned From Outbreaks of Shiga Toxin Producing Escherichia coli

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Vorhofflimmern bei Jüngeren gefährlicher als gedacht

06.05.2024 Vorhofflimmern Nachrichten

Immer mehr jüngere Menschen leiden unter Vorhofflimmern. Betroffene unter 65 Jahren haben viele Risikofaktoren und ein signifikant erhöhtes Sterberisiko verglichen mit Gleichaltrigen ohne die Erkrankung.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise